Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF CASH FLOWS

v3.23.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - CAD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Cash provided from operating activities:      
Net loss $ (191,301) $ (18,518) [1] $ (28,734)
Adjustments for non-cash items:      
Unrealized gain on changes in fair value of biological assets (84) (7,210) (11,781)
Fair value adjustment on sale of inventory 4,342 8,796 10,122
Fair value adjustment on Warrants, Investments, and Accounts Receivable (6,000) (21,638) 20,155
Depreciation of property, plant and equipment 3,044 3,021 690
Amortization of intangible assets 2,343 1,158 31
Depreciation of right-of-use assets 1,944 1,550 209
Impairment of goodwill 107,854 275 0
Impairment of property, plant and equipment 2,277 0 0
Impairment of intangible assets 7,199 0 0
Impairment of right-of-use assets 1,914 0 0
Finance income, net 6,532 1,262 72
Deferred tax payments (benefit), net (3,004) 278 (66)
Share-based payments 3,767 7,471 3,382
Share based acquisition costs related to business combination 0 807 0
Revaluation of other accounts receivable 3,982 0 0
Restructuring expenses 8,757 0 0
Total adjustments for non-cash items 144,867 (4,230) 22,814
Changes in non-cash working capital:      
Increase (decrease) in trade receivables, net 6,058 (6,602) (3,534)
Increase (decrease) in other accounts receivable and advances to suppliers 3,622 845 (1,029)
Decrease in biological assets, net of fair value adjustments 565 6,412 11,771
Increase (decrease) in inventory, net of fair value adjustments 883 (19,707) (12,729)
Increase in trade payables 11,284 5,573 2,135
Changes in employee benefit liabilities, net (63) 28 59
Increase in other accounts payable and accrued expenses 12,126 2,661 1,929
Changes in non-cash working capital 34,475 (10,790) (1,398)
Taxes paid (681) (834) (601)
Net cash used in operating activities (12,640) (34,372) (7,919)
Cash flows from investing activities:      
Purchase of property, plant and equipment (1,562) (4,578) (2,617)
Proceeds from sales of property, plant and equipment 210 0 0
Proceeds from loans receivable 350 7,796 0
Purchase of intangible assets 0 (17) (93)
Acquisition of businesses, net of cash acquired 0 (12,536) 0
Deconsolidation of subsidiary (406) 0 0
Investments in financial assets 0 (13) (1,347)
Proceeds from sale of investment 0 319 0
Proceeds from (investment in) restricted deposits 0 17 (18)
Net cash used in investing activities (1,408) (9,012) (4,075)
Cash provided by financing activities:      
Proceeds from issuance of share capital, net of issuance costs 3,756 28,131 0
Proceeds from issuance of warrants measured at fair value 0 11,222 0
Proceeds from exercise of warrants 0 3,682 6,378
Proceeds from exercise of options 333 133 612
Repayment of lease liability (1,656) (633) (182)
Payment of lease liability interest (1,429) (1,347) (68)
Proceeds from loans 9,636 7,804 0
Repayment of loans (4,976) 0 0
Interest paid (902) (261) 0
Net cash provided by financing activities 4,762 48,731 6,740
Effect of foreign exchange on cash and cash equivalents (2,168) (329) 213
Increase (decrease) in cash and cash equivalents (11,454) 5,018 (5,041)
Cash and cash equivalents at beginning of year 13,903 8,885 13,926
Cash and cash equivalents at end of year 2,449 13,903 8,885
Supplemental disclosure of non-cash activities:      
Right-of-use asset recognized with corresponding lease liability 613 1,678 107
Conversion of warrant and compensation options into common shares 0 611 0
Issuance of shares in payment of purchase consideration liability $ 3,061 $ 0 $ 0
[1] Reclassified in respect of discontinued operations - see Note 24.